Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry
Authors:
- Daniela MilizianoDMDaniela Miliziano
- Julia K. RotowJRJulia K. Rotow
- Meghanne LomibaoMLMeghanne Lomibao
- Arianna MarinelloAMArianna Marinello
- Helena Bote-De CaboHCHelena Bote-De Cabo
- Fabrizio CitarellaFCFabrizio Citarella
- Lorenza LandiLLLorenza Landi
- Massimiliano CaniMCMassimiliano Cani
- Mariana BrandãoMBMariana Brandão
- Jamie FengJFJamie Feng
- Sophie CousinSCSophie Cousin
- Andrea De GiglioAndrea De Giglio
- 12 November 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Abstract
Purpose: Selective RET inhibitors (SRI) are the first-line standard for RET fusion–positive non–small cell lung cancer, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental Design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum–pemetrexed (Pt-Pem) with or without immunotherapy (IO) after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly Pt-Pem with or without IO (n = 35, 54%). At 53 months’ median follow-up, the real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) was 6.1 months [95% confidence interval (CI), 4.8–11.4], and median overall survival (OS) was 13.7 months (95% CI, 8.7–26.5). Outcomes were similar with chemotherapy alone (n = 12) versus chemoimmunotherapy (n = 23) for rwPFS [5.9 vs. 6.8 months; hazard ratio (HR), 1.05; P = 0.903] and OS (18.5 vs. 13.7 months; HR, 0.83; P = 0.674). Three patients had rwPFS beyond 24 months with chemoimmunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was the most common (n = 11), with no responses and a median rwPFS of 1.5 months (95% CI, 0.8–NR). Conclusions: Second-line Pt-Pem with or without IO achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.Keywords
Funding Information
- National Cancer Institute (R01CA259177)
- National Cancer Institute (P30CA008748)
- Université Paris-Saclay (DUERTECC/EURONCO)
- Fondazione AIRC per la ricerca sul cancro ETS (30915)
- Happy Lungs